Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Polivy
Pharma
ASCO: Incyte positions Monjuvi combo for first-line DLBCL
Incyte believes a consistent PFS benefit across patient subgroups will give its seven-drug Monjuvi combo an edge over a Polivy regimen by Roche.
Angus Liu
May 30, 2026 8:00am
Incyte to seek FDA approval for Monjuvi in front-line DLBCL
Jan 5, 2026 10:40am
Roche’s bispecific-ADC combo keeps lymphoma at bay
Jun 23, 2025 10:27am
Roche's Vabysmo crosses $4B mark as Polivy joins blockbuster club
Jan 30, 2025 11:06am
ASH: Lilly defends survival data blemish in novel BTK trial win
Dec 9, 2024 5:45pm
AZ's Enhertu, Akeso's bispecifics win reimbursement in China
Dec 4, 2024 12:52pm
